Krystal Biotech has outlined its non-GAAP operating expenses for 2026 to be between $175 million and $195 million, while also planning for six data readouts before the end of the year.

Several financial firms have issued new ratings, price targets, or coverage initiations for biotech and pharmaceutical companies including Beam Therapeutics, Krystal Biotech, 4D Molecular Therapeutics, BioMarin Pharmaceutical, Vertex Pharmaceuticals, CRISPR Therapeutics AG, Regeneron Pharmaceuticals, and UniQure.

Krystal Biotech plans to expand VYJUVEK globally, with a launch in Italy scheduled for the second half of 2026, while maintaining a strong gross margin outlook.

Krystal Biotech exceeded both revenue and earnings estimates for the fourth quarter and has initiated its financial outlook for fiscal year 2026.

Krystal Biotech and Axsome Therapeutics have released their latest quarterly financial results. Krystal Biotech reported GAAP EPS and revenue that both beat analyst expectations, while Axsome Therapeutics beat revenue estimates but missed on GAAP EPS.

A biotech investor has increased their stake in Krystal Biotech by $3 million, as the company reported revenues reaching $389 million in 2025.

A summary of Krystal Biotech, Inc.'s Q4 2025 earnings call outlines the company's financial performance and strategic updates.

Jefferies has increased its price target for Krystal Biotech, Inc. (KRYS) to $371, while maintaining a Buy rating on the stock.

Krystal Biotech's Q4 earnings call highlights are now available, detailing the company's financial performance and outlook.